Teladoc Health Reports Fourth Quarter and Full Year 2021 Results

• Fourth quarter revenue grows 45% year-over-year to $554.2 million and total visits increase 41% to 4.4 million
  
  
• Full year revenue grows 86% year-over-year to $2,032.7 million and total visits increase 38% to 15.4 million
  
  
• Full year cash flows from operations grew to $194.0 million
  
  
• Full year 2022 Revenue guidance of $2.55 to $2.65 billion, representing 25% to 30% growth
  

PURCHASE, NY, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in whole-person virtual care, today reported financial results for the fourth quarter and full year ended December 31, 2021.  

“Teladoc Health took a huge step forward in bringing true whole-person care to life for consumers and clients in 2021,” said Jason Gorevic, chief executive officer of Teladoc Health. “We successfully delivered against performance metrics, solidified our position as the partner of choice for our clients and connected millions of consumers with high-quality care. Our commitment to be the first stop along the consumer healthcare journey – regardless of need – remains unwavering. And Teladoc Health is clearly differentiated by the breadth and depth of our offerings, an integrated suite of virtual care services that connect individuals with chronic, primary, acute and specialty care. We saw meaningful growth and penetration across several key areas of our business, in mental health through both BetterHelp in the direct-to-consumer space and our new MyStrength Complete B2B2C approach to right care at the right time, as well as primary care through Primary 360, all helping to meet a greater share of an individual’s healthcare needs.”

“Healthcare has a ‘new normal’ resulting from the pandemic’s intersection of health needs and virtual solutions that has forever changed the experience of healthcare. We are proud of the role Teladoc Health has played in leading this transformation and are equally excited about our role in 2022 and beyond as we continue to innovate, further evolving whole-person care, introducing new services like Chronic Care Complete, expanding into new markets and deepening our relationships with our clients and consumers," Gorevic added.

Key Financial Data
($ thousands, unaudited)
		Quarter Ended								Year over Year		Year Ended								Year over Year
		December 31,								Change		December 31,								Change
		2021				2020						2021				2020
Revenue		$	554,235			$	383,321			45%		$	2,032,707			$	1,093,962			86%
Net Loss		$	(10,985	)		$	(393,967	)		nm		$	(428,793	)		$	(485,136	)		nm
Net Loss per share, basic and diluted		$	(0.07	)		$	(3.07	)		nm		$	(2.73	)		$	(5.36	)		nm
Adjusted EBITDA*		$	77,077			$	50,384			53%		$	267,837			$	126,841			111%
Cash Flow from Operations		$	83,208			$	(114,936	)		nm		$	193,990			$	(53,511	)		nm

* A reconciliation of each non-GAAP measure to the most comparable measure under GAAP has been provided in this press release in the accompanying tables. An explanation of these Non-GAAP measures is also included below under the heading “Non-GAAP Financial Measures.”
nm – Not meaningful

Fourth Quarter 2021

Revenue increased 45% to $554.2 million, from $383.3 million in the fourth quarter of 2020. Access fees revenue grew 51% to $469.9 million and visit fee revenue grew 21% to $68.9 million. U.S. Revenues grew 45% to $482.9 million and International revenues grew 40% to $71.3 million.

Net loss totaled $11.0 million, or $(0.07) per share, compared to $394.0 million, or $(3.07) per share, in the fourth quarter of 2020. Results for the fourth quarter of 2021 included stock-based compensation expense of $61.6 million, or $(0.39) per share, amortization of acquired intangibles of $45.1 million, or $(0.28) per share, and non-cash income tax benefit of $49.7 million, or $0.31 per share.

Results for the fourth quarter of 2020 included stock-based compensation expense of $414.4 million, or $(3.23) per share, amortization of acquired intangibles of $33.0 million, or $(0.26) per share, and non-cash income tax benefit of $85.5 million, or $0.67 per share.

Adjusted EBITDA* increased 53% to $77.1 million, compared to $50.4 million in the fourth quarter of 2020.

GAAP Gross margin, which includes depreciation and amortization, was 67.5 percent for the fourth quarter of 2021 compared to 67.2 percent for the fourth quarter of 2020.

Adjusted Gross margin* was 68.4 percent for the fourth quarter of 2021 compared to 67.9 percent for the fourth quarter of 2020.

Average revenue per U.S. paid member increased to $2.49 in the fourth quarter of 2021, from $1.63 in the fourth quarter of 2020 and $2.40 in the third quarter of 2021.

Full Year Ended December 31, 2021

Revenue increased 86% to $2,032.7 million, from $1,094.0 million for the year ended December 31, 2020. Access fees revenue grew 104% to $1,732.0 million and visit fee revenue grew 15% to $254.2 million. U.S. Revenues grew 94% to $1,774.0 million and International revenues grew 44% to $258.7 million.

Net loss totaled $428.8 million, or $(2.73) per share, compared to $485.1 million, or $(5.36) per share, for the year ended December 31, 2021. Results for the year ended December 31, 2021 included stock-based compensation expense of $302.6 million, or $(1.93) per share, amortization of acquired intangibles of $178.9 million, or $(1.14) per share, loss on extinguishment of debt of $43.7 million, or $(0.28) per share, and non-cash income tax expense of $44.1 million, or $(0.28) per share.

Results for the year ended December 31, 2020 included stock-based compensation expense $475.5 million, or $(5.25) per share, amortization of acquired intangibles $57.5 million, or $(0.64) per share, loss on extinguishment of debt $9.1 million, or $(0.10) per share, and non-cash income tax benefit $90.9 million, or $1.00 per share.

Adjusted EBITDA* increased 111% to $267.8 million, compared to $126.8 million in 2020.

GAAP Gross margin, which includes depreciation and amortization, was 67.2 percent for the full year 2021 compared to 63.1 percent in 2020.

Adjusted Gross margin* was 68.0 percent for the full year 2021 compared to 64.3 percent in 2020.

Financial Outlook
Teladoc Health provides guidance based on current market conditions and expectations and what we know today. In addition, given the uncertainty of the expected path of the COVID-19 pandemic as well as the broader economic impact, this is an evolving situation and circumstances may change. Based on what we know today, we believe our guidance ranges provide a reasonable baseline for 2022 financial performance.

For the first quarter of 2022, we expect:

	1Q 2022 Guidance Range
Revenue	$565 to $571 million
EBITDA	$(23) to $(16) million
Adjusted EBITDA	$51 to $55 million
Net loss per share	$(0.60) to $(0.50) per share
Total U.S. Paid Membership	54.0 to 54.5 million members
Visit Fee Only Access	24.0 to 25.0 million
Total Visits	4.3 to 4.5 million visits

For the full year 2022, we expect:

	Full Year 2022 Guidance Range
Revenue	$2.55 to $2.65 billion
EBITDA	$18 to $48 million
Adjusted EBITDA	$330 to $355 million
Net loss per share	$(1.60) to $(1.40) per share
Total U.S. Paid Membership	54.0 to 56.0 million members
Visit Fee Only Access	24.0 to 25.0 million
Total Visits	18.5 to 20.0 million visits

Earnings Conference Call

The fourth quarter and full year 2021 earnings conference call and webcast will be held Tuesday, February 22, 2022 at 4:30 p.m. E.T. The conference call can be accessed by dialing 1-844-200-6205 for U.S. participants, or 1-929-526-1599 for international participants, and referencing Conference ID Number: 335463; or via a live audio webcast available online at http://ir.teladoc.com/news-and-events/events-and-presentations/. A webcast replay will be available for on-demand listening shortly after the completion of the call at the same web link, and will remain available for approximately 90 days.

About Teladoc Health

Teladoc Health empowers all people everywhere to live their healthiest lives by transforming the healthcare experience. As the world leader in whole-person virtual care, Teladoc Health uses proprietary health signals and personalized interactions to drive better health outcomes across the full continuum of care, at every stage in a person’s health journey. Ranked best in KLAS for Virtual Care Platforms in 2020 and #1 among direct-to-consumer telehealth providers in the J.D. Power 2021 U.S. Telehealth Satisfaction Study, Teladoc Health leverages more than a decade of expertise and data-driven insights to meet the growing virtual care needs of consumers and healthcare professionals. For more information, please visit www.teladochealth.com or follow @TeladocHealth on Twitter.

Cautionary Note Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “believe,” “project,” “estimate,” “expect,” “may,” “should,” “will” and similar references to future periods. Examples of forward-looking statements include, among others, statements we make regarding future financial or operating results, future numbers of members or clients, future numbers of visits, litigation outcomes, regulatory developments, market developments, new products and growth strategies, and the effects of any of the foregoing on our future results of operations or financial condition.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: (i) changes in laws and regulations applicable to our business model; (ii) changes in market conditions and receptivity to our services and offerings; (iii) results of litigation; (iv) the loss of one or more key clients; (v) changes in valuations or useful lives of our assets; (vi) changes to our abilities to recruit and retain qualified providers into our network; and (vii) the impact of the COVID-19 pandemic on our operations, demand for our services and general economic conditions, as well as orders, directives and legislative action by local, state, federal and foreign governments in response to the spread of COVID-19. For a detailed discussion of the risk factors that could affect our actual results, please refer to the risk factors identified in our SEC reports, including, but not limited to, our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as filed with the SEC.

Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Revenues and Summary Operating Metrics
Revenue (1)
($ thousands)		Quarter Ended						Year over Year			Year Ended						Year over Year
		December 31,						Growth			December 31,						Growth
		2021			2020						2021			2020
Access Fees Revenue
U.S.		$	403,095		$	263,220		53	%		$	1,488,420		$	678,168		119	%
International			66,821			48,954		36	%			243,585			169,087		44	%
Total			469,916			312,174		51	%			1,732,005			847,255		104	%
Visit Fee Revenue
U.S.			65,328			55,437		18	%			241,515			211,664		14	%
International			3,588			1,608		123	%			12,719			9,792		30	%
Total			68,916			57,045		21	%			254,234			221,456		15	%
Other
U.S.			14,472			13,589		6	%			44,089			23,888		85	%
International			931			513		81	%			2,379			1,363		75	%
Total			15,403			14,102		9	%			46,468			25,251		84	%
Total Revenue		$	554,235		$	383,321		45	%		$	2,032,707		$	1,093,962		86	%
U.S. Revenue		$	482,895		$	332,246		45	%		$	1,774,024		$	913,720		94	%
International Revenue			71,340			51,075		40	%			258,683			180,242		44	%
Total Revenue		$	554,235		$	383,321		45	%		$	2,032,707		$	1,093,962		86	%
Average U.S. Revenue Per Member (2)		$	2.49		$	1.63		52	%

Visits (1)
(thousands)		Quarter Ended						Year over Year			Year Ended						Year over Year
		December 31,						Growth			December 31,						Growth
		2021			2020						2021			2020
U.S. Visits		3,291			2,289			44	%		11,482			8,083			42	%
International Visits		1,116			828			35	%		3,917			3,096			27	%
Total Visits		4,407			3,117			41	%		15,399			11,179			38	%
Utilization (3)		22.7	%		16.0	%		668	pt		20.1	%		14.5	%		563	pt
Platform-Enabled Sessions (4)		982			1,089			(10	)%		4,060			2,076			96	%
Total Visits & Sessions Provided & Enabled		5,389			4,206			28	%		19,459			13,255			47	%

Membership and Visit Fee Only Access
(millions)		Year Ended
		December 31,						Growth
		2021			2020
U.S. Paid Membership		53.6			51.8			3	%
U.S. Visit Fee Only Access		24.2			21.3			14	%
Chronic Care Enrollment		0.729			0.596			22	%

(1) During the fourth quarter of 2021, Teladoc Health, Inc. (“Teladoc Health” or “the Company”) refined its definition of international revenues to reflect all international revenues based on location of the customer. Previously, direct to consumer activities were primarily reflected based on the location of operations. In addition, certain activities related to our international operations are now reflected in visit revenues versus access fee revenues. Prior period amounts have been recast to conform with current presentation. Consistent with this change, the corresponding metrics have been updated, including the addition of approximately 590,000 and 588,000 visits for 2021 and 2020, respectively.

(2) Average U.S. Revenue Per Member measures the average quarterly amount of access revenue that the Company generates from a U.S. paid member. It is calculated by dividing the quarterly U.S. access revenue generated from the Company’s U.S. paid members, excluding certain non-member based access fees, by the total average number of U.S. paid members during the quarter.

(3) Utilization measures the ratio of visits to total U.S. paid members. It is calculated by dividing monthly visits by monthly U.S. paid members in the quarter and annualizing the result. Visit fee only visits are excluded.

(4) Platform-Enabled Sessions are a unique instance in which our licensed software platform has facilitated a virtual voice or video encounter between a care provider and our client’s patient, or between care providers. We believe platform-enabled sessions are an indicator of the value our clients derive from the platform they license from us in order to facilitate virtual care.

TELADOC HEALTH, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except share and per share data, unaudited)
		Quarter Ended December 31,								Year Ended December 31,
		2021				2020				2021				2020
Revenue		$	554,235			$	383,321			$	2,032,707			$	1,093,962
Expenses:
Cost of revenue (exclusive of depreciation and amortization, which is shown separately below)			174,985				122,942				650,258				390,829
Operating expenses:
Advertising and marketing			112,988				93,751				416,726				226,146
Sales			59,330				93,942				250,581				154,052
Technology and development			72,867				92,697				311,884				164,941
Acquisition, integration, and transformation costs			4,559				57,550				26,643				88,236
General and administrative			118,603				343,985				438,007				506,684
Depreciation and amortization			52,332				36,960				204,239				69,495
Total expenses			595,664				841,827				2,298,338				1,600,383
Loss from operations			(41,429	)			(458,506	)			(265,631	)			(506,421	)
Loss on extinguishment of debt			20				99				43,748				9,077
Other expense (income), net			405				(282	)			(5,088	)			545
Interest expense, net			18,872				21,101				80,365				59,950
Net loss before taxes			(60,726	)			(479,424	)			(384,656	)			(575,993	)
Income tax (benefit) expense			(49,741	)			(85,457	)			44,137				(90,857	)
Net loss		$	(10,985	)		$	(393,967	)		$	(428,793	)		$	(485,136	)
Net loss per share, basic and diluted		$	(0.07	)		$	(3.07	)		$	(2.73	)		$	(5.36	)
Weighted-average shares used to compute basic and diluted net loss per share			159,944,335				128,298,005				156,939,349				90,509,229

Stock-based Compensation Summary

Compensation costs for stock-based awards were classified as follows (in thousands):

		Quarter Ended								Year Ended
		December 31,								December 31,
		2021				2020				2021				2020
Cost of revenue (exclusive of depreciation and amortization, which is shown separately)		$	1,970			$	2,572			$	8,280			$	2,700
Advertising and marketing			3,811				22,548				18,952				26,995
Sales			13,837				56,265				71,475				65,730
Technology and development			18,226				53,271				95,561				60,556
General and administrative			23,771				279,724				108,318				319,550
Total stock-based compensation expense (1)		$	61,615			$	414,380			$	302,586			$	475,531

(1) Excluding the amount capitalized related to internal software development projects.

TELADOC HEALTH, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands, unaudited)
		Year Ended December 31,
		2021				2020
Operating activities:
Net loss		$	(428,793	)		$	(485,136	)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation and amortization			204,239				69,495
Depreciation of rental equipment			3,333				1,697
Amortization of right-of-use assets			12,049				6,895
Provision for doubtful accounts			16,941				5,284
Stock-based compensation			302,586				475,531
Deferred income taxes			41,800				(90,158	)
Accretion of interest			61,253				45,296
Loss on extinguishment of debt			40,652				9,077
Gain on sale of investment			(5,901	)			0
Other, net			(3,845	)			(1,009	)
Changes in operating assets and liabilities:
Accounts receivable			(17,510	)			(21,091	)
Prepaid expenses and other current assets			(31,090	)			(12,565	)
Inventory			(19,494	)			(24,732	)
Other assets			(3,547	)			(8,135	)
Accounts payable			1,188				(87,995	)
Accrued expenses and other current liabilities			18,175				20,125
Accrued compensation			(4,675	)			34,819
Deferred revenue			20,554				17,751
Operating lease liabilities			(16,532	)			(6,300	)
Other liabilities			2,607				(2,360	)
Net cash provided by (used in) operating activities			193,990				(53,511	)
Investing activities:
Capital expenditures			(8,534	)			(4,024	)
Capitalized software			(55,400	)			(22,018	)
Proceeds from marketable securities			50,000				2,496
Proceeds from the sale of investment			10,901				0
Acquisitions of business, net of cash acquired			(78,663	)			(567,429	)
Other, net			8,715				0
Net cash used in investing activities			(72,981	)			(590,975	)
Financing activities:
Net proceeds from the exercise of stock options			25,781				54,314
Proceeds from issuance of 2027 Notes			0				1,000,000
Payment of issuance costs of 2027 Notes			0				(24,070	)
Repurchase of 2022 Notes			(139	)			(228,153	)
Proceeds from the sale of capped call related to the Livongo Notes			0				91,659
Proceeds from advances from financing companies			15,275				6,002
Payment against advances from financing companies			(16,050	)			(8,635	)
Payment of assumed indebtedness			0				(10,000	)
Proceeds from employee stock purchase plan			16,810				4,722
Cash received (paid) for withholding taxes on stock-based compensation, net			3,422				(26,703	)
Other, net			(4,152	)			0
Net cash provided by financing activities			40,947				859,136
Net increase in cash and cash equivalents			161,956				214,650
Foreign exchange difference			(1,800	)			4,321
Cash and cash equivalents at beginning of the period			733,324				514,353
Cash and cash equivalents at end of the period		$	893,480			$	733,324
Income taxes paid		$	3,974			$	1,324
Interest paid		$	16,430			$	14,890

TELADOC HEALTH, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except share and per share data, unaudited)

		December 31,				December 31,
		2021				2020
Assets
Current assets:
Cash and cash equivalents		$	893,480			$	733,324
Short-term investments			2,537				53,245
Accounts receivable, net of provision of $12,384 and $6,412, respectively			168,956				169,281
Inventories			73,079				56,498
Prepaid expenses and other current assets			87,387				47,259
Total current assets			1,225,439				1,059,607
Property and equipment, net			27,234				28,551
Goodwill			14,504,174				14,581,255
Intangible assets, net			1,910,278				2,020,864
Operating lease - right-of-use assets			46,780				46,647
Other assets			20,703				18,357
Total assets		$	17,734,608			$	17,755,281
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable		$	47,257			$	46,030
Accrued expenses and other current liabilities			102,933				83,657
Accrued compensation			91,941				94,593
Deferred revenue-current			75,569				52,356
Advances from financing companies			13,313				13,453
Current portion of long-term debt			—				42,560
Total current liabilities			331,013				332,649
Other liabilities			1,492				1,616
Operating lease liabilities, net of current portion			41,773				43,142
Deferred revenue, net of current portion			3,834				2,449
Advances from financing companies, net of current portion			9,291				9,926
Deferred taxes, net			75,777				102,103
Convertible senior notes, net			1,225,671				1,379,592
Commitments and contingencies
Stockholders’ equity:
Common stock, $0.001 par value; 300,000,000 shares authorized as of December 31, 2021 and 2020; 160,469,325 shares and 150,281,099 shares issued and outstanding as of December 31, 2021 and 2020, respectively			160				150
Additional paid-in capital			17,473,336				16,857,797
Accumulated deficit			(1,421,454	)			(992,661	)
Accumulated other comprehensive (loss) gain			(6,285	)			18,518
Total stockholders’ equity			16,045,757				15,883,804
Total liabilities and stockholders’ equity		$	17,734,608			$	17,755,281

Non-GAAP Financial Measures:

To supplement our financial information presented in accordance with GAAP, we use adjusted gross profit, adjusted gross margin, EBITDA, and adjusted EBITDA, which are non-GAAP financial measures, to clarify and enhance an understanding of past performance. We believe that the presentation of these financial measures enhances an investor’s understanding of our financial performance. We further believe that these financial measures are useful financial metrics to assess our operating performance and financial and business trends from period-to-period by excluding certain items that we believe are not representative of our core business. We use certain financial measures for business planning purposes and in measuring our performance relative to that of our competitors. We utilize adjusted EBITDA as the primary measure of our performance.

Adjusted gross profit is our total revenue minus our total cost of revenue (exclusive of depreciation and amortization, which is shown separately) and adjusted gross margin is adjusted gross profit as a percentage of our total revenue.

EBITDA consists of net loss before interest; other expense (income), net, including foreign exchange gain or loss; taxes; depreciation and amortization; and loss on extinguishment of debt. Adjusted EBITDA consists of net loss before interest; other expense (income), net, including foreign exchange gain or loss; taxes; depreciation and amortization; loss on extinguishment of debt; stock-based compensation; and acquisition, integration and transformation costs.

We believe the above financial measures are commonly used by investors to evaluate our performance and that of our competitors. However, our use of the terms adjusted gross profit, adjusted gross margin, EBITDA, and adjusted EBITDA may vary from that of others in our industry. None of adjusted gross profit, adjusted gross margin, EBITDA, nor adjusted EBITDA should be considered as an alternative to net loss before taxes, net loss, net loss per share or any other performance measures derived in accordance with GAAP.

Adjusted gross profit, adjusted gross margin, EBITDA, and adjusted EBITDA have important limitations as analytical tools and you should not consider them in isolation or as a substitute for analysis of our results as reported under GAAP. Some of these limitations are:

• Adjusted gross margin has been and will continue to be affected by a number of factors, including the fees we charge our clients, the number of visits and cases we complete, the costs paid to providers and medical experts, as well as the costs of our provider network operations center;
• Adjusted gross margin does not reflect the significant depreciation and amortization to cost of revenue;
• EBITDA and adjusted EBITDA do not reflect the significant interest expense on our debt;
• EBITDA and adjusted EBITDA eliminate the impact of income taxes on our results of operations;
• EBITDA and adjusted EBITDA do not reflect the loss on extinguishment of debt;
• EBITDA and adjusted EBITDA do not reflect other expense (income), net;
• Adjusted EBITDA does not reflect the significant acquisition, integration and transformation costs. Acquisition, integration and transformation costs include investment banking, financing, legal, accounting, consultancy, integration, fair value changes related to contingent consideration and certain other transaction costs related to mergers and acquisitions. It also includes costs related to certain business transformation initiatives focused on integrating and optimizing various operations and systems, including upgrading our customer relationship management (CRM) and enterprise resource planning (ERP) systems. These transformation cost adjustments made to our results do not represent normal, operating expenses necessary to operate the business but rather, incremental costs incurred in connection with our acquisition and integration activities;
• Adjusted EBITDA does not reflect the significant non-cash stock compensation expense which should be viewed as a component of recurring operating costs; and
• other companies in our industry may calculate adjusted gross profit, adjusted gross margin, EBITDA, and adjusted EBITDA differently than we do, limiting the usefulness of these measures as comparative measures.
  

In addition, although depreciation and amortization are non-cash charges, the assets being depreciated and amortized will often have to be replaced in the future, and adjusted gross profit, adjusted gross margin, EBITDA and adjusted EBITDA do not reflect any expenditures for such replacements.

We compensate for these limitations by using adjusted gross profit, adjusted gross margin, EBITDA, and adjusted EBITDA along with other comparative tools, together with GAAP measurements, to assist in the evaluation of operating performance. Such GAAP measurements include net loss, net loss per share, and other performance measures.

In evaluating these financial measures, you should be aware that in the future we may incur expenses similar to those eliminated in this presentation. Our presentation of adjusted gross profit, adjusted gross margin, EBITDA, and adjusted EBITDA should not be construed as an inference that our future results will be unaffected by unusual or nonrecurring items.

The following is a reconciliation of gross profit and gross margin, the most directly comparable GAAP financial measures, to adjusted gross profit and adjusted gross margin, respectively:

Reconciliation of GAAP Gross Profit to Adjusted Gross Profit and Adjusted Gross Margin (In thousands, unaudited)
		Quarter Ended								Year Ended
		December 31,								December 31,
		2021				2020				2021				2020
Revenue		$	554,235			$	383,321			$	2,032,707			$	1,093,962
Cost of revenue (exclusive of depreciation and amortization, which is shown separately below)			(174,985	)			(122,942	)			(650,258	)			(390,829	)
Depreciation and amortization of intangible assets			(5,406	)			(2,846	)			(16,546	)			(12,394	)
Gross Profit			373,844				257,533				1,365,903				690,739
Depreciation and amortization of intangible assets			5,406				2,846				16,546				12,394
Adjusted gross profit		$	379,250			$	260,379			$	1,382,449			$	703,133
Gross margin			67.5	%			67.2	%			67.2	%			63.1	%
Adjusted gross margin			68.4	%			67.9	%			68.0	%			64.3	%

The following is a reconciliation of Net Loss, the most directly comparable GAAP financial measure, to EBITDA and adjusted EBITDA:

Reconciliation of GAAP Net Loss to EBITDA and Adjusted EBITDA (In thousands, except for guidance data, unaudited)
	Quarter Ended								Year Ended								Guidance in millions (1)
	December 31,								December 31,								First Quarter		Full Year
	2021				2020				2021				2020				2022		2022
Net loss	$	(10,985	)		$	(393,967	)		$	(428,793	)		$	(485,136	)		$(91) - $(81)		$(259) - $(213)
Add:
Loss on extinguishment of debt		20				99				43,748				9,077
Other expense (income), net		405				(282	)			(5,088	)			545
Interest expense, net		18,872				21,101				80,365				59,950
Income tax (benefit) expense		(49,741	)			(85,457	)			44,137				(90,857	)
Depreciation and amortization		52,332				36,960				204,239				69,495
Total loss on extinguishment of debt; other expense (income), net; interest expense, net; income tax (benefit) expense; and depreciation and amortization		21,888				(27,579	)			367,401				48,210			68 - 65		277 - 261
EBITDA		10,903				(421,546	)			(61,392	)			(436,926	)		(23) - (16)		18 - 48
Stock-based compensation		61,615				414,380				302,586				475,531
Acquisition, integration, and transformation costs		4,559				57,550				26,643				88,236
Total stock-based compensation and acquisition, integration, and transformation costs		66,174				471,930				329,229				563,767			74 - 71		312 - 307
Adjusted EBITDA	$	77,077			$	50,384			$	267,837			$	126,841			$51 - $55		$330 - $355

(1) We have not provided a full line-item reconciliation for net loss to EBITDA or adjusted EBITDA guidance because we do not provide guidance on the individual reconciling items between net loss, EBITDA, and adjusted EBITDA. This is due to the uncertainty as to timing, and the potential variability, of the individual reconciling items such as stock-based compensation and the related tax impact, income taxes and acquisition, integration and transformation costs, the effect of which may be significant. Accordingly, a full line-item reconciliation of the GAAP measure to the corresponding non-GAAP financial measure guidance is not available without unreasonable effort.

Revenues and Selected Operating Metrics (1)
(In thousands, except Average U.S. Revenue per Member)
		1Q				2Q				3Q				4Q				1Q				2Q				3Q				4Q
Revenue		2020				2020				2020				2020				2021				2021				2021				2021
Access Fees Revenue
U.S.		$	99,917			$	138,396			$	176,635			$	263,220			$	327,553			$	371,591			$	386,181			$	403,095
International			34,147				40,187				45,799				48,954				54,553				59,474				62,737				66,821
Total			134,064				178,583				222,434				312,174				382,106				431,065				448,918				469,916
Visit Fee Revenue
U.S.			44,043				59,556				52,628				55,437				57,128				59,196				59,863				65,328
International			2,692				2,891				2,601				1,608				3,383				3,058				2,690				3,588
Total			46,735				62,447				55,229				57,045				60,511				62,254				62,553				68,916
Other
U.S.			-				-				10,299				13,589				10,671				9,363				9,583				14,472
International			-				-				850				513				387				457				604				931
Total			-				-				11,149				14,102				11,058				9,820				10,187				15,403
Total Revenue		$	180,799			$	241,030			$	288,812			$	383,321			$	453,675			$	503,139			$	521,658			$	554,235
U.S. Revenue		$	143,960			$	197,952			$	239,562			$	332,246			$	395,352			$	440,150			$	455,627			$	482,895
International Revenue			36,839				43,078				49,250				51,075				58,323				62,989				66,031				71,340
Total Revenue		$	180,799			$	241,030			$	288,812			$	383,321			$	453,675			$	503,139			$	521,658			$	554,235
Average U.S. Revenue per Member		$	0.80			$	0.92			$	1.06			$	1.63			$	2.09			$	2.31			$	2.40			$	2.49
Visits
U.S. Visits			1,514				2,108				2,172				2,289				2,461				2,723				3,007				3,291
International Visits			706				769				793				828				881				929				991				1,116
Total Visits			2,220				2,877				2,965				3,117				3,342				3,652				3,998				4,407
U.S. Paid Membership			42.9				51.5				51.5				51.8				51.5				52.0				52.5				53.6
Utilization			12.1	%			14.4	%			14.8	%			16.0	%			17.5	%			19.1	%			21.0	%			22.7	%
Platform-Enabled Sessions			n/a				n/a				987				1,089				1,092				1,017				969				982
Total Visits & Sessions Provided & Enabled			2,220				2,877				3,952				4,206				4,434				4,669				4,967				5,389

(1) During the fourth quarter of 2021, the Company refined its definition of international revenues to reflect all international revenues based on location of the customer. Previously, direct to consumer activities were primarily reflected based on the location of operations. In addition, certain activities related to our international operations are now reflected in visit revenues versus access fee revenues. Prior period amounts have been recast to conform with current presentation. Consistent with this change, the corresponding metrics have been updated.

n/a – Not applicable

Investors:
Patrick Feeley
914-265-7925
IR@teladochealth.com 

Media:
Chris Stenrud
860-491-8821
pr@teladochealth.com